AU2014229020B2 - Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same - Google Patents

Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same Download PDF

Info

Publication number
AU2014229020B2
AU2014229020B2 AU2014229020A AU2014229020A AU2014229020B2 AU 2014229020 B2 AU2014229020 B2 AU 2014229020B2 AU 2014229020 A AU2014229020 A AU 2014229020A AU 2014229020 A AU2014229020 A AU 2014229020A AU 2014229020 B2 AU2014229020 B2 AU 2014229020B2
Authority
AU
Australia
Prior art keywords
antibody
seq
masp
sgmi
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014229020A
Other languages
English (en)
Other versions
AU2014229020A1 (en
Inventor
W. Jason Cummings
Patrick Gray
Larry W. Tjoelker
Munehisa Yabuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omeros Corp
Original Assignee
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Medical Systems Inc filed Critical Omeros Medical Systems Inc
Publication of AU2014229020A1 publication Critical patent/AU2014229020A1/en
Application granted granted Critical
Publication of AU2014229020B2 publication Critical patent/AU2014229020B2/en
Priority to AU2017276336A priority Critical patent/AU2017276336A1/en
Priority to AU2019226184A priority patent/AU2019226184B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
AU2014229020A 2013-03-15 2014-03-14 Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same Active AU2014229020B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017276336A AU2017276336A1 (en) 2013-03-15 2017-12-15 Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
AU2019226184A AU2019226184B2 (en) 2013-03-15 2019-09-05 Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361962289P 2013-03-15 2013-03-15
US61/962,289 2013-03-15
US201361823964P 2013-05-16 2013-05-16
US61/823,964 2013-05-16
PCT/US2014/028999 WO2014144542A2 (en) 2013-03-15 2014-03-14 Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017276336A Division AU2017276336A1 (en) 2013-03-15 2017-12-15 Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same

Publications (2)

Publication Number Publication Date
AU2014229020A1 AU2014229020A1 (en) 2015-10-29
AU2014229020B2 true AU2014229020B2 (en) 2017-09-28

Family

ID=51538337

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014229020A Active AU2014229020B2 (en) 2013-03-15 2014-03-14 Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
AU2017276336A Abandoned AU2017276336A1 (en) 2013-03-15 2017-12-15 Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
AU2019226184A Active AU2019226184B2 (en) 2013-03-15 2019-09-05 Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017276336A Abandoned AU2017276336A1 (en) 2013-03-15 2017-12-15 Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
AU2019226184A Active AU2019226184B2 (en) 2013-03-15 2019-09-05 Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same

Country Status (8)

Country Link
US (3) US20150017162A1 (enExample)
EP (1) EP2968546B1 (enExample)
JP (2) JP2016514456A (enExample)
AU (3) AU2014229020B2 (enExample)
CA (1) CA2906096C (enExample)
ES (1) ES2964340T3 (enExample)
NZ (2) NZ729747A (enExample)
WO (1) WO2014144542A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140363433A1 (en) * 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
CA2906096C (en) * 2013-03-15 2022-03-15 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
EA201790946A8 (ru) * 2014-12-01 2018-10-31 Зе Скриппс Рисёрч Инститьют Способы и композиции, связанные с функциональными полипептидами, встроенными в гетерологичные белковые каркасы
CA3010593C (en) * 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
AU2017342428B2 (en) * 2016-10-13 2021-02-04 Omeros Corporation Methods for reducing proteinuria in a human subject suffering from immunoglobulin a Nephropathy
US11827717B2 (en) 2017-04-03 2023-11-28 Chugai Seiyaku Kabushiki Kaisha Anti-MASP-1 antibodies and methods of use
CN110709417B (zh) * 2017-04-07 2023-10-31 美天施生物科技有限责任两合公司 具有突变人IgG4的多肽
CN112313333A (zh) * 2018-05-10 2021-02-02 秘来生物制剂株式会社 包含抗体的抗原结合区、融合生理活性肽的人工蛋白质
CA3139209A1 (en) 2019-05-07 2020-11-12 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
TWI867422B (zh) 2020-03-06 2024-12-21 美商奥默羅斯公司 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
CA3200103A1 (en) 2020-11-04 2022-05-12 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
EP4011904A1 (en) 2020-12-14 2022-06-15 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
WO2022228364A1 (zh) * 2021-04-25 2022-11-03 江苏恒瑞医药股份有限公司 抗masp2抗体、其抗原结合片段及医药用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110091450A1 (en) * 2009-10-16 2011-04-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
WO2012007777A1 (en) * 2010-07-13 2012-01-19 Eötvös Loránd Tudományegyetem Novel proteins, process for preparation thereof, and use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US20050033033A1 (en) * 1998-05-04 2005-02-10 Heinz Kohler Trans-membrane-antibody induced inhibition of apoptosis
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
KR100490669B1 (ko) * 2001-08-30 2005-05-19 (주)아비코아생명공학연구소 조류 콕시듐증을 유발하는 에이메리아 종의 포자소체 표면항원에 대한 ｓｃＦｖ 재조합 항체
WO2004002417A2 (en) * 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
EP1531757B1 (en) 2002-07-19 2016-09-07 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
KR20060006775A (ko) * 2003-03-05 2006-01-19 이넥스 바이오테크놀로지 인크. 세포자살을 억제하는 유도된 막 횡단 항체
HUE034760T2 (en) 2003-05-12 2018-02-28 Helion Biotech Aps Masp-2-T binding antibodies
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20130266559A1 (en) 2004-06-10 2013-10-10 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
WO2007048022A2 (en) * 2005-10-21 2007-04-26 Alexion Pharmaceuticals, Inc. Antibody-polypeptide fusion proteins and methods for producing and using same
AR056806A1 (es) * 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
JP5537420B2 (ja) 2007-05-31 2014-07-02 ユニヴァーシティ オブ ワシントン 標的遺伝子の誘導性変異誘発
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
JP5901517B2 (ja) * 2009-05-28 2016-04-13 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 抗原結合性タンパク質
WO2012000777A1 (en) 2010-07-01 2012-01-05 Thomson Licensing Method for calibrating a band rejection filter of a terminal and multistandard terminal with calibrated band rejection filter
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
DK2694108T3 (en) * 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
HUE049154T2 (hu) 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
US8961981B2 (en) * 2011-06-20 2015-02-24 Saint Louis University Targeting the neuromuscular junction for treatment
NZ629675A (en) * 2012-04-06 2017-02-24 Omeros Corp Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
PT2861246T (pt) 2012-06-18 2021-04-05 Univ Leicester Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
CA2906096C (en) * 2013-03-15 2022-03-15 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110091450A1 (en) * 2009-10-16 2011-04-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
WO2012007777A1 (en) * 2010-07-13 2012-01-19 Eötvös Loránd Tudományegyetem Novel proteins, process for preparation thereof, and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. HEJA ET AL, JOURNAL OF BIOLOGICAL CHEMISTRY, (2012-06-08), vol. 287, no. 24, pages 20290 - 20300 *
LI LINGNA ET AL, TRANSLATIONAL ONCOLOGY, (2011-08-01), vol. 4, no. 4, pages 249 -257 *

Also Published As

Publication number Publication date
EP2968546B1 (en) 2023-09-20
AU2014229020A1 (en) 2015-10-29
CA2906096A1 (en) 2014-09-18
EP2968546A4 (en) 2016-11-02
JP6615854B2 (ja) 2019-12-04
CA2906096C (en) 2022-03-15
WO2014144542A3 (en) 2014-12-31
EP2968546A2 (en) 2016-01-20
NZ629682A (en) 2017-03-31
NZ729747A (en) 2020-03-27
US20210079117A1 (en) 2021-03-18
AU2019226184A1 (en) 2019-09-26
JP2016514456A (ja) 2016-05-23
ES2964340T3 (es) 2024-04-05
US20250122309A1 (en) 2025-04-17
WO2014144542A2 (en) 2014-09-18
JP2018093875A (ja) 2018-06-21
AU2017276336A1 (en) 2018-01-18
US20150017162A1 (en) 2015-01-15
AU2019226184B2 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
US20250122309A1 (en) Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
US11613589B2 (en) Compositions for inhibiting MASP-2 dependent complement activation
JP6608702B2 (ja) 補体関連疾患の予防及び治療のためのｃ５抗体及び方法
US20250282879A1 (en) Multispecific antibodies having specificity for il-4r and il-31
AU2015384281B2 (en) Novel antibody binding to TFPI and composition comprising the same
US12344663B2 (en) Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
CN103339150A (zh) 抗缓激肽b2受体(bkb2r)单克隆抗体
CN105189551A (zh) 抗-rankl抗体及其使用方法
CA2827759C (en) Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
US11045544B2 (en) Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
US20260055180A1 (en) Kidney targeting antibodies
A. Vousden et al. Engineering approaches to develop the next generation of antibodies to respiratory targets
HK1242343B (en) Compositions for inhibiting masp-2 dependent complement activation
HK1242343A1 (en) Compositions for inhibiting masp-2 dependent complement activation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)